Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.53
Bid: 1.53
Ask: 1.60
Change: -0.002 (-0.13%)
Spread: 0.07 (4.575%)
Open: 1.53
High: 1.53
Low: 1.53
Prev. Close: 1.567
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: Hemogenyx hopes on cancer drug; IDE loss widens

Thu, 29th Sep 2022 15:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Brandshield Systems PLC - London-based cybersecurity solutions provider - Interim loss widens despite revenue jump as costs balloon. Pretax loss in the half-year to June 30 widens to USD4.1 million from USD1.8 million a year ago. Revenue grows 60% to USD2.8 million from USD1.8 million. Operating expenses surge to USD5.5 million from USD2.8 million. Trading for 2022 is in line with management expectations, Chief Executive Officer Yoav Keren says. "Growth in client numbers and associated annual recurring revenue remains incredibly encouraging and the board is resolute in its strategy of reinforcing this as the market opportunity continues to present itself. The company looks forward to updating the market in our full year results building on what is traditionally a very strong final quarter of the year and the foundations laid in our recently expanded sales and marketing efforts," he adds.

----------

Hemogenyx Pharmaceuticals PLC - London-based biotechnology company focused on blood diseases - Interim loss narrows as finance costs decrease. Pretax loss in the six months to June 30 narrows to GBP1.1 million from GBP3.6 million a year prior. Posts no revenue in either period. Finance costs narrow to GBP17 from GBP2.7 million. Administrative expenses flat at GBP1.1 million. Firm focuses on a comprehensive investigational new drug application for HEMO-CAR-T, Chair Marc Feldmann explains. HEMO-CAR-T is a therapy targeting acute myeloid leukaemia, a form of cancer of white blood cells.

----------

IDE Group Holdings PLC - Edinburgh-based network, cloud and IT managed services - Annual loss widens as costs outpace revenue growth amid one-off impairment charge. Pretax loss in 2021 widens to GBP3.0 million from GBP2.8 million in 2020. Revenue grows 25% to GBP14.5 million from GBP11.5 million. Finance costs widen by 38% to GBP2.5 million from GBP1.8 million. Administrative costs increase 16% to GBP6.8 million from GBP5.9 million. Notes one-off impairment charge of GBP1.8 million in 2021. Regarding the impairment charge, firm explains: "The directors performed an impairment review in respect of software licences, which had a carrying amount at the previous balance sheet date of GBP1.8 million. The impairment review was triggered both because the licences were not yet in use, and because of an indicator of impairment due to planned expansion which didn't materialise, and the sale of the Connect business, which meant the licences had no addressable market."

----------

Trafalgar Property Group PLC - Kent-based residential homes developer - Annual loss widens as revenue plummets. In the year that ended March 31, pretax loss widens to GBP486,336 from GBP329,194 a year prior. Revenue drops to GBP64,839 from GBP2.3 million. "Revenue represents the amounts receivable from the investment in residential property during the year and other income directly associated with property development. This will take the form of rental income and sales of investment property," Trafalgar explains. "The effects of the Covid-19 pandemic have affected our business since March 2020 as sales of completed units have been delayed with the planning process being negatively impacted. Like most businesses, we are aware of our need to conduct ourselves carefully to preserve the health of our staff and customers and to conserve our cash reserves," Chair James Dubois says.

----------

By Tom Budszus; tombudszus@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 12:19

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

Read more
16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases.

Read more
14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections.

Read more
9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.

Read more
2 Feb 2024 10:44

IN BRIEF: Hemogenyx hails US patent application progress

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.

Read more
16 Jan 2024 11:13

Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Tuesday said it submitted a complete response to the previously announced clinical hold of the investigational new drug application to the US Food & Drug Administration.

Read more
8 Jan 2024 10:56

Hemogenyx Pharmaceuticals completes process qualification run

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it completed a process qualification run.

Read more
28 Nov 2023 16:53

TRADING UPDATES: Upland Resources completes technical study at Sarawak

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Nov 2023 10:52

Hemogenyx shares up as says CBR platform a potential cancer treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said its chimeric based receptor platform could "potentially" be used to treat cancer and viral diseases.

Read more
15 Nov 2023 15:43

Hemogenyx Pharmaceuticals completes lentivirus re-manufacture

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said it has completed the re-manufacturing of an improved lentivirus devoid of splice variants.

Read more
28 Sep 2023 14:24

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Sep 2023 14:37

TRADING UPDATES: Avingtrans buys Adaptix, TPXimpact sells Questers

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
18 Sep 2023 13:00

Hermogenyx shares soar on new partnership with Prevail Partners

(Sharecast News) - Shares in biopharma group Hemogenyx surged on Monday after the company received a $0.83m investment from Prevail Partners as it continues to work on its planned clinical trial for leukaemia treatment.

Read more
14 Sep 2023 14:31

Hemogenyx Pharma says US FDA accepts Hemo-Car-T clinical hold lift plan

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said the US Food & Drug Administration has accepted its plan to address concerns which sparked a clinical hold on its chimeric antigen receptor T-cell or Hemo-Car-T therapy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.